Costs and possible benefits of a two-tier infection control management strategy consisting of active screening for multidrug-resistant organisms and tailored control measures

Background: Multidrug-resistant organisms (MDROs) are an economic burden, and infection control (IC) measures are cost-and labour-intensive. A two-tier IC management strategy was developed, including active screening, in order to achieve effective use of limited resources. Briefly, high-risk patients were differentiated from other patients, distinguished according to type of MDRO, and IC measures were implemented accordingly. Aim: To evaluate costs and benefits of this IC management strategy. Methods: The study period comprised 2.5 years. All high-risk patients underwent microbiological screening. Gram-negative bacteria (GNB) were classified as multidrug-resistant (MDR) and extensively drug-resistant (XDR). Expenses consisted of costs for staff, materials, laboratory, increased workload and occupational costs. Findings: In total, 39,551 patients were screened, accounting for 24.5% of all admissions. Of all screened patients, 7.8% (N = 3,104) were MDRO positive; these patients were mainly colonized with vancomycin-resistant enterococci (37.3%), followed by meticillin-resistant Staphylococcus aureus (30.3%) and MDR-GNB (28.3%). The median length of stay (LOS) for all patients was 10 days (interquartile range 3-20); LOS was twice as long in colonized patients (P < 0.001). Screening costs totalled 255,093.82(sic), IC measures cost 97,701.36(sic), and opportunity costs were 599,225.52(sic). The savings of this IC management strategy totalled 500,941.84(sic). Possible transmissions by undetected carriers would have caused additional costs of 613,648.90-4,974,939.26(sic) (i.e. approximately 600,000-5 million (sic)). Conclusion: Although the costs of a two-tier IC management strategy including active microbiological screening are not trivial, these data indicate that the approach is cost-effective when prevented transmissions are included in the cost estimate. (C) 2016 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.